Literature DB >> 17533199

NADPH oxidase contributes to vascular inflammation, insulin resistance, and remodeling in the transgenic (mRen2) rat.

Yongzhong Wei1, Adam T Whaley-Connell, Kemin Chen, Javad Habibi, Grace M-E Uptergrove, Suzanne E Clark, Craig S Stump, Carlos M Ferrario, James R Sowers.   

Abstract

Reduced insulin sensitivity is characteristic of various pathological conditions such as type 2 diabetes mellitus and hypertension. Angiotensin II, acting through its angiotensin type 1 receptor, inhibits the actions of insulin in the vasculature which may lead to deleterious effects such as vascular inflammation, remodeling, endothelial dysfunction, and insulin resistance. In contrast, insulin normally exerts vasodilatory, antiinflammatory, and prosurvival actions. To explore the impact of angiotensin II on insulin signaling, NADPH oxidase-derived reactive oxygen species formation, vascular inflammation, apoptosis, and remodeling, we used transgenic TG(mRen2)27 (Ren2) rats, which harbor the mouse renin transgene and exhibits elevated tissue angiotensin II levels. Compared with Sprague-Dawley controls, Ren2 aortas exhibited greater NADPH oxidase activity, reactive oxygen species levels, C-reactive protein, tumor necrosis factor-alpha expression, apoptosis, and wall thickness, which were significantly attenuated by in vivo treatment with angiotensin type 1 receptor blockade (valsartan) or the superoxide dismutase/catalase mimetic (tempol). There was substantially diminished Akt and endothelial NO synthase activation in Ren2 aortas in response to in vivo insulin stimulation, and this was significantly improved by in vivo treatment with valsartan or tempol. In vivo treatment with valsartan, but not tempol, significantly reduced blood pressure in Ren2 rats. Further, there was reduced insulin induced Akt activation and increased tumor necrosis factor-alpha levels in vascular smooth muscle cells from Ren2 and Sprague-Dawley rats treated with angiotensin II, abnormalities that were abrogated by angiotensin type 1 receptor blockade with valsartan or antioxidant N-acetylcysteine. Collectively, these data suggest that increased angiotensin type 1 receptor/NADPH oxidase activation/reactive oxygen species contribute to vascular insulin resistance, endothelial dysfunction, apoptosis, and inflammation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17533199     DOI: 10.1161/HYPERTENSIONAHA.107.089284

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  47 in total

Review 1.  Vascular oxidative stress: the common link in hypertensive and diabetic vascular disease.

Authors:  Richard A Cohen; XiaoYong Tong
Journal:  J Cardiovasc Pharmacol       Date:  2010-04       Impact factor: 3.105

Review 2.  Role of angiotensin II receptor subtype activation in cognitive function and ischaemic brain damage.

Authors:  Masatsugu Horiuchi; Masaki Mogi
Journal:  Br J Pharmacol       Date:  2011-07       Impact factor: 8.739

3.  Nebivolol improves diastolic dysfunction and myocardial remodeling through reductions in oxidative stress in the Zucker obese rat.

Authors:  Xinli Zhou; Lixin Ma; Javad Habibi; Adam Whaley-Connell; Melvin R Hayden; Roger D Tilmon; Ashley N Brown; Jeong-A Kim; Vincent G Demarco; James R Sowers
Journal:  Hypertension       Date:  2010-02-22       Impact factor: 10.190

Review 4.  Differential metabolic actions of specific statins: clinical and therapeutic considerations.

Authors:  Soo Lim; Ichiro Sakuma; Michael J Quon; Kwang Kon Koh
Journal:  Antioxid Redox Signal       Date:  2013-09-24       Impact factor: 8.401

Review 5.  Angiotensin II-dependent superoxide: effects on hypertension and vascular dysfunction.

Authors:  William J Welch
Journal:  Hypertension       Date:  2008-05-12       Impact factor: 10.190

6.  Dietary sodium restriction decreases insulin secretion without affecting insulin sensitivity in humans.

Authors:  James M Luther; Loretta M Byrne; Chang Yu; Thomas J Wang; Nancy J Brown
Journal:  J Clin Endocrinol Metab       Date:  2014-07-16       Impact factor: 5.958

Review 7.  Resistance to insulin and kidney disease in the cardiorenal metabolic syndrome; role for angiotensin II.

Authors:  Ravi Nistala; Adam Whaley-Connell
Journal:  Mol Cell Endocrinol       Date:  2013-02-15       Impact factor: 4.102

8.  Direct inhibition by angiotensin II of insulin-dependent glucose transport activity in mammalian skeletal muscle involves a ROS-dependent mechanism.

Authors:  Maggie K Diamond-Stanic; Erik J Henriksen
Journal:  Arch Physiol Biochem       Date:  2010-05       Impact factor: 4.076

9.  Nebivolol reduces proteinuria and renal NADPH oxidase-generated reactive oxygen species in the transgenic Ren2 rat.

Authors:  Adam Whaley-Connell; Javad Habibi; Megan Johnson; Roger Tilmon; Nathan Rehmer; Jenna Rehmer; Charles Wiedmeyer; Carlos M Ferrario; James R Sowers
Journal:  Am J Nephrol       Date:  2009-07-17       Impact factor: 3.754

10.  Angiotensin-converting enzyme is a modifier of hypertensive end organ damage.

Authors:  Xiaojun Liu; Christopher O C Bellamy; Matthew A Bailey; Linda J Mullins; Donald R Dunbar; Christopher J Kenyon; Gillian Brooker; Surasak Kantachuvesiri; Klio Maratou; Ali Ashek; Allan F Clark; Stewart Fleming; John J Mullins
Journal:  J Biol Chem       Date:  2009-03-23       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.